These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1955905)

  • 1. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
    Atack JR; Litvan I; Thal LJ; May C; Rapoport SI; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 Sep; 54(9):832-5. PubMed ID: 1955905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems.
    Ruberg M; Villageois A; Bonnet AM; Pillon B; Rieger F; Agid Y
    J Neurol Neurosurg Psychiatry; 1987 May; 50(5):538-43. PubMed ID: 2953866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type.
    Atack JR; May C; Kaye JA; Kay AD; Rapoport SI
    Ann Neurol; 1988 Feb; 23(2):161-7. PubMed ID: 3377438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
    Appleyard ME; McDonald B
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1074-8. PubMed ID: 1469405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inhibitor-free assay of acetylcholinesterase and butyrylcholinesterase in the cerebrospinal fluid.
    Kluge HH; Kluge WH; Hartmann W
    Clin Chim Acta; 1999 Apr; 282(1-2):135-45. PubMed ID: 10340441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease.
    Sirviö J; Soininen HS; Kutvonen R; Hyttinen JM; Helkala EL; Riekkinen PJ
    J Neurol Sci; 1987 Nov; 81(2-3):273-9. PubMed ID: 3694232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid.
    Atack JR; Perry EK; Bonham JR; Perry RH
    J Neurochem; 1987 Jun; 48(6):1845-50. PubMed ID: 3572402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
    Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
    J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
    Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
    Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study.
    Frattali CM; Sonies BC; Chi-Fishman G; Litvan I
    Dysphagia; 1999; 14(3):165-8. PubMed ID: 10341115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs.
    Mattio T; McIlhany M; Giacobini E; Hallak M
    Neuropharmacology; 1986 Oct; 25(10):1167-77. PubMed ID: 3785584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities and kinetic properties of lumbar cerebrospinal fluid cholinesterases in relation to clinical diagnosis, severity, and progression of Alzheimer's disease.
    Huff FJ; Reiter CT; Protetch J
    Can J Neurol Sci; 1989 Nov; 16(4):406-10. PubMed ID: 2804802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine.
    Bansal I; Waghmare CK; Anand T; Gupta AK; Bhattacharya BK
    J Appl Toxicol; 2009 Jul; 29(5):386-94. PubMed ID: 19283689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CSF acetylcholinesterase activity in central neurological diseases involving cholinergic systems].
    Konagaya M; Konagaya Y; Iida M
    Rinsho Shinkeigaku; 1992 Mar; 32(3):266-71. PubMed ID: 1628449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterases in cerebrospinal fluid. A longitudinal study in Alzheimer disease.
    Elble R; Giacobini E; Scarsella GF
    Arch Neurol; 1987 Apr; 44(4):403-7. PubMed ID: 3827696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders.
    Davis KL; Hollister LE; Livesey J; Berger PA
    Psychopharmacology (Berl); 1979 May; 63(2):155-9. PubMed ID: 157494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease.
    Ruberg M; Rieger F; Villageois A; Bonnet AM; Agid Y
    Brain Res; 1986 Jan; 362(1):83-91. PubMed ID: 3942870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia.
    Hirano S; Shinotoh H; Shimada H; Aotsuka A; Tanaka N; Ota T; Sato K; Ito H; Kuwabara S; Fukushi K; Irie T; Suhara T
    Brain; 2010 Jul; 133(Pt 7):2058-68. PubMed ID: 20558417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.